Antibody-drug conjugate · Cytotoxic, directed at carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) · developed by BeOne Medicines
BG-C477 is an antibody-drug conjugate in which a monoclonal antibody binds CEACAM5, a cell adhesion protein overexpressed on many cancer cells, and delivers an undisclosed cytotoxic agent after internalization. It is studied in advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06596473 | Phase 1 | Advanced Solid Tumors | Recruiting | ONC |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid Tumors
Updated Oct 25, 2026. Something wrong or missing? Report it on the ONC page.
See ONC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ONC catalysts and pipeline →